Molina Healthcare (MOH) · Health Insurance
Molina Healthcare Q2 2026 earnings: summary, key numbers & outlook
Results filed 22 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Molina is exiting traditional Medicare Advantage Prescription Drug plans for 2027 to focus exclusively on dual eligible members, while Marketplace shrinks sharply and Medicaid is called the 2026 trough.
Molina's business is being reshaped. Marketplace membership fell to 283,000 from 690,000 a year earlier, and Medicaid membership declined to 4,418,000. Medicare was the bright spot, with lower medical cost trend and 2026 pricing helping it run better than management expected. The company also took an impairment on its traditional Medicare Advantage Prescription Drug product, which it will exit for 2027 to focus exclusively on dual eligible members.
Management calls 2026 the trough year for Medicaid margins and expects future rate increases to correct the gap between rates and medical cost trend. It points to a retained $2 billion Managed Medicaid contract in Illinois and a 2027 premium outlook of approximately $46.5 billion. The tension is execution: a new Florida Medicaid contract starts in the fourth quarter of 2026 with a guided loss, and Marketplace acuity mix remains unfavorable.
No call transcript for this quarter, so this summary also draws on: allmind.ai ↗.
Key numbers
- Total revenue · GAAP
- $10.9B
- Net income · GAAP
- $60 million
- Diluted EPS · GAAP
- $1.19
- Adjusted diluted EPS · non-GAAP
- $1.51
- Operating cash flow (six months) · GAAP
- $788 million
- Consolidated medical care ratio · GAAP
- 92.2%
a decrease of 76% year over year
a decrease of 76% year over year
a decrease of 74% year over year
compared to an outflow of $112 million for the six months ended June 30, 2025
| Segment or metric | Value | Change |
|---|---|---|
| Medicaid premium revenue | $8.0B | |
| Medicare premium revenue | 1.6B | |
| Marketplace premium revenue | 628.0M | |
| Total members | approximately 4.9 million | |
| Marketplace members | 283,000 |
Where each number comes from
- Total revenue: “Total Revenue | $10,874 | $11,427 | $21,670 | $22,574 GAAP: Net Income | $60 | $255 | $74 | $553”
- Net income: “GAAP net income for the second quarter of 2026 was $60 million, or $1.19 per diluted share, a decrease of 76% year over year.”
- Diluted EPS: “GAAP net income for the second quarter of 2026 was $60 million, or $1.19 per diluted share, a decrease of 76% year over year.”
- Adjusted diluted EPS: “Adjusted net income for the second quarter of 2026 was $77 million, or $1.51 per diluted share, a decrease of 74% year over year.”
- Operating cash flow (six months): “Operating cash flow for the six months ended June 30, 2026, was $788 million, compared to an outflow of $112 million for the six months ended June 30, 2025.”
- Consolidated medical care ratio: “The consolidated MCR for the second quarter of 2026 was 92.2%.”
- Medicaid premium revenue: “Medicaid | $8,049 | $585 | 92.7% | $8,029 | $697 | 91.3% Medicare | 1,565 | 146 | 90.7 | 1,608 | 161 | 90.0”
- Medicare premium revenue: “Medicaid | $8,049 | $585 | 92.7% | $8,029 | $697 | 91.3% Medicare | 1,565 | 146 | 90.7 | 1,608 | 161 | 90.0”
- Marketplace premium revenue: “Marketplace | 628 | 69 | 88.9 | 1,200 | 175 | 85.4 Other (2) | 2 | 4 | NM | 31 | 6 | NM”
- Total members: “As of June 30, 2026, the Company served approximately 4.9 million members.”
- Marketplace members: “Marketplace | 283,000 | 655,000 | 690,000 Other | 1,000 | 6,000 | 15,000 Total | 4,926,000 | 5,491,000 | 5,746,000”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $10.9B | −4.8% | +0.7% |
| Operating income | $145.0M | −61.1% | +74.7% |
| Net income | $60.0M | −76.5% | +328.6% |
| Diluted EPS | $1.19 | −74.9% | +340.7% |
| Free cash flow | -$324.0M | +5.8% | — |
| Operating margin | 1.3% | −2.0 pts | +0.5 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted EPS | full year 2026 | at least $5.25 |
| GAAP EPS | full year 2026 | at least $2.15 |
| Premium revenue | full year 2026 | approximately $42 billion |
| Florida Medicaid contract implementation loss per share | full year 2026 | $1.50 per share |
Key takeaways
Molina will exit traditional MAPD for 2027
The company took an impairment because the Medicare Advantage Prescription Drug product does not fit its shift to focus exclusively on dual eligible members. The product is also expected to lose $1.00 per share in 2026, and management plans to reduce its footprint further to limit exposure.
Marketplace membership more than halved year over year
Marketplace membership was 283,000 at June 30, 2026, versus 690,000 a year earlier. Marketplace MCR was higher than expected because of prior year risk adjustment, program integrity initiatives and unfavorable member acuity mix.
Management says 2026 is the Medicaid margin trough
The CEO said the imbalance between Medicaid rates and medical cost trend appears to have stabilized and is positioned to be corrected by future rate increases. Medicaid MCR was in line with expectations, reflecting rate updates and stable medical cost trend.
Illinois Managed Medicaid contract of $2 billion retained
Molina kept the contract in Illinois, which it describes as a very large Medicaid state for it. Retaining large state contracts is central to rebuilding premium volume after membership declines.
New Florida Medicaid contract weighs on 2026
Full year guidance includes a loss of $1.50 per share from implementing the new Florida Medicaid contract in the fourth quarter of 2026. It is a near-term cost of the contract that management expects to build toward 2027 growth.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $10.5B * |
| Q1 2025 | $11.1B |
| Q2 2025 | $11.4B |
| Q3 2025 | $11.5B |
| Q4 2025 | $11.4B * |
| Q1 2026 | $10.8B |
| Q2 2026 | $10.9B |
| Q3 2026 | $11.1B |
Data
| Q1 2025 | $5.45 |
| Q2 2025 | $4.75 |
| Q3 2025 | $1.51 |
| Q1 2026 | $0.27 |
| Q2 2026 | $1.19 |
| Q3 2026 | $0.73 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 3.6% |
| Q1 2025 | 3.9% |
| Q2 2025 | 3.3% |
| Q3 2025 | 1.2% |
| Q4 2025 | -1.4% |
| Q1 2026 | 0.8% |
| Q2 2026 | 1.3% |
| Q3 2026 | 1.0% |
Data
| Q4 2024 | -$235.0M |
| Q1 2025 | $168.0M |
| Q2 2025 | -$344.0M |
| Q3 2025 | -$163.0M |
| Q4 2025 | -$297.0M |
| Q1 2026 | $1.1B |
| Q2 2026 | -$324.0M |
| Q3 2026 | -$196.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What is Molina doing with its Medicare business?
It will exit the traditional Medicare Advantage Prescription Drug product for 2027 and focus exclusively on dual eligible members. It reported a Medicare MCR of 90.7%, better than its expectation, helped by lower medical cost trend and 2026 pricing.
Why does Molina call 2026 a trough year for Medicaid?
Management says the imbalance between Medicaid rates and medical cost trend appears to have stabilized and should be corrected by future rate increases. It believes the premium and EPS building blocks position it for profitable growth in 2027.
What happened to Molina's Marketplace business?
Marketplace membership fell to 283,000 from 690,000 a year earlier. Its MCR was higher than expected due to prior year risk adjustment, program integrity initiatives and unfavorable member acuity mix, and guidance for the segment was revised down.
What is Molina's outlook for 2027 premiums?
Management put the 2027 premium outlook at approximately $46.5 billion before capturing any remaining items. It also retained a $2 billion Managed Medicaid contract in Illinois.
How is the new Florida Medicaid contract affecting 2026?
Implementation in the fourth quarter of 2026 is expected to cost $1.50 per share in full year guidance. Molina counts the contract among the building blocks for 2027.
Documents
SEC filing